Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK
Author:
Publisher
Elsevier BV
Subject
Radiology Nuclear Medicine and imaging,Oncology
Reference18 articles.
1. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer;Vergote;N Engl J Med,2010
2. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial;Kehoe;Lancet,2015
3. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial;Katsumata;Lancet,2009
4. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial;Katsumata;Lancet Oncol,2013
5. Incorporation of bevacizumab in the primary treatment of ovarian cancer;Burger;N Engl J Med,2011
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease;Annals of Oncology;2024-02
2. MDT practice determines treatment pathway for patients with advanced ovarian cancer: A multi-centre observational study;European Journal of Surgical Oncology;2023-08
3. British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer;Cancers;2023-01-04
4. Value of pre-existent bacterial colonization in patients with advanced/relapsed ovarian neoplasms undergoing cytoreductive surgery: a multicenter observational study (BONSAI);International Journal of Gynecologic Cancer;2020-08-18
5. Tanshinone IIA induces apoptosis of ovarian cancer cells in�vitro and in�vivo through attenuation of PI3K/AKT/JNK signaling pathways;Oncology Letters;2018-11-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3